IDEXX Laboratories (IDXX) in our Pivotal Point Check: Pet Health Specialist Increases Q3 Revenue by 13% to $1.1 Billion – Outlook for 2025 Raised to $4.30 Billion!

IDEXX reports better-than-expected results in both earnings per share and revenue for Q3. The 2025 outlook for revenue and earnings has been raised. The core business of pet diagnostics remains the main growth driver, especially recurring revenues. IDEXX is a specialist in diagnostic products and services in veterinary medicine. The main business is the Companion Animal Group (CAG), which provides veterinarians with laboratory services, diagnostic devices, and tests for pets such as dogs and cats. The company significantly benefits...